{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:46:45Z","timestamp":1780966005433,"version":"3.54.1"},"reference-count":108,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"German Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019563","name":"Institute of Microbiology of the Czech Academy of Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100019563","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004240","name":"Akademie V\u011bd \u010cesk\u00e9 Republiky","doi-asserted-by":"publisher","award":["86652036"],"award-info":[{"award-number":["86652036"]}],"id":[{"id":"10.13039\/501100004240","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001824","name":"Czech Science Foundation","doi-asserted-by":"publisher","award":["24-12155S"],"award-info":[{"award-number":["24-12155S"]}],"id":[{"id":"10.13039\/501100001824","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Computers in Biology and Medicine"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.compbiomed.2025.110695","type":"journal-article","created":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T13:05:22Z","timestamp":1751634322000},"page":"110695","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"PA","title":["In silico screening of a designed focused chemical space identifies novel alkyl hydrazides as potent HDAC11 inhibitors"],"prefix":"10.1016","volume":"196","author":[{"given":"Fady","family":"Baselious","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Hilscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3393-6787","authenticated-orcid":false,"given":"Lukas","family":"Handke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2751-3060","authenticated-orcid":false,"given":"Cyril","family":"Barinka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike","family":"Schutkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5985-9261","authenticated-orcid":false,"given":"Wolfgang","family":"Sippl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.compbiomed.2025.110695_bib1","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.sbi.2011.08.004","article-title":"Structure, mechanism, and inhibition of histone deacetylases and related metalloenzymes","volume":"21","author":"Lombardi","year":"2011","journal-title":"Curr. Opin. Struct. Biol."},{"issue":"5","key":"10.1016\/j.compbiomed.2025.110695_bib2","doi-asserted-by":"crossref","DOI":"10.3390\/genes11050556","article-title":"Histone deacetylases (HDACs): Evolution, specificity, role in transcriptional complexes, and pharmacological actionability","volume":"11","author":"Milazzo","year":"2020","journal-title":"Genes"},{"issue":"28","key":"10.1016\/j.compbiomed.2025.110695_bib3","doi-asserted-by":"crossref","first-page":"25748","DOI":"10.1074\/jbc.M111871200","article-title":"Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family","volume":"277","author":"Gao","year":"2002","journal-title":"J. Biol. Chem."},{"issue":"10","key":"10.1016\/j.compbiomed.2025.110695_bib4","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.1111\/febs.15895","article-title":"HDAC11: a multifaceted histone deacetylase with proficient fatty deacylase activity and its roles in physiological processes","volume":"289","author":"N\u00fa\u00f1ez-\u00c1lvarez","year":"2022","journal-title":"FEBS J."},{"issue":"12","key":"10.1016\/j.compbiomed.2025.110695_bib5","doi-asserted-by":"crossref","first-page":"5487","DOI":"10.1073\/pnas.1815365116","article-title":"HDAC11 regulates type I interferon signaling through defatty-acylation of SHMT2","volume":"116","author":"Cao","year":"2019","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"1","key":"10.1016\/j.compbiomed.2025.110695_bib6","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/ni.1673","article-title":"The histone deacetylase HDAC11 regulates the expression of interleukin 10 and immune tolerance","volume":"10","author":"Villagra","year":"2009","journal-title":"Nat. Immunol."},{"issue":"2","key":"10.1016\/j.compbiomed.2025.110695_bib7","first-page":"983","article-title":"Inhibition of histone deacetylase 11 promotes human liver cancer cell apoptosis","volume":"11","author":"Gong","year":"2019","journal-title":"Am J Transl Res"},{"issue":"12","key":"10.1016\/j.compbiomed.2025.110695_bib8","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1002\/cbin.10834","article-title":"Histone deacetylase 11 suppresses p53 expression in pituitary tumor cells","volume":"41","author":"Wang","year":"2017","journal-title":"Cell Biol. Int."},{"issue":"1","key":"10.1016\/j.compbiomed.2025.110695_bib9","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/s41392-023-01333-7","article-title":"Epigenetic regulation in metabolic diseases: mechanisms and advances in clinical study","volume":"8","author":"Wu","year":"2023","journal-title":"Signal Transduct. Targeted Ther."},{"issue":"8","key":"10.1016\/j.compbiomed.2025.110695_bib10","doi-asserted-by":"crossref","first-page":"5582","DOI":"10.1002\/jcp.30286","article-title":"The role of HDAC11 in obesity-related metabolic disorders: a critical review","volume":"236","author":"Yang","year":"2021","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.compbiomed.2025.110695_bib11","article-title":"HDAC11, an emerging therapeutic target for metabolic disorders","volume":"13","author":"Chen","year":"2022","journal-title":"Front. Endocrinol."},{"issue":"Pt 1","key":"10.1016\/j.compbiomed.2025.110695_bib12","article-title":"HDAC11 deficiency resists obesity by converting adipose-derived stem cells into brown adipocyte-like cells","volume":"258","author":"Yang","year":"2024","journal-title":"Int. J. Biol. Macromol."},{"issue":"12","key":"10.1016\/j.compbiomed.2025.110695_bib13","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1016\/j.bmcl.2018.05.021","article-title":"Discovery of novel N-hydroxy-2-arylisoindoline-4-carboxamides as potent and selective inhibitors of HDAC11","volume":"28","author":"Martin","year":"2018","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"1","key":"10.1016\/j.compbiomed.2025.110695_bib14","doi-asserted-by":"crossref","first-page":"4722","DOI":"10.1038\/s41598-020-61295-6","article-title":"Novel HDAC11 inhibitors suppress lung adenocarcinoma stem cell self-renewal and overcome drug resistance by suppressing Sox 2","volume":"10","author":"Bora-Singhal","year":"2020","journal-title":"Sci. Rep."},{"issue":"23","key":"10.1016\/j.compbiomed.2025.110695_bib15","doi-asserted-by":"crossref","first-page":"16075","DOI":"10.1021\/acs.jmedchem.3c01491","article-title":"Development and pharmacochemical characterization discover a novel brain-permeable HDAC11-Selective inhibitor with therapeutic potential by regulating neuroinflammation in mice","volume":"66","author":"Bai","year":"2023","journal-title":"J. Med. Chem."},{"issue":"10","key":"10.1016\/j.compbiomed.2025.110695_bib16","doi-asserted-by":"crossref","DOI":"10.1002\/ardp.202400486","article-title":"Utilization of an optimized AlphaFold protein model for structure-based design of a selective HDAC11 inhibitor with anti-neuroblastoma activity","volume":"357","author":"Baselious","year":"2024","journal-title":"Arch Pharm (Weinheim)"},{"key":"10.1016\/j.compbiomed.2025.110695_bib17","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25021358","article-title":"Comparative structure-based virtual screening utilizing optimized AlphaFold model identifies selective HDAC11 inhibitor","volume":"25","author":"Baselious","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.compbiomed.2025.110695_bib18","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1021\/acschembio.7b00942","article-title":"Histone deacetylase 11 is a fatty-acid deacylase","volume":"13","author":"Kutil","year":"2018","journal-title":"ACS Chem. Biol."},{"issue":"7","key":"10.1016\/j.compbiomed.2025.110695_bib19","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.chembiol.2018.04.007","article-title":"Histone deacetylase 11 is an \u03b5-N-Myristoyllysine hydrolase","volume":"25","author":"Moreno-Yruela","year":"2018","journal-title":"Cell Chem. Biol."},{"issue":"22","key":"10.1016\/j.compbiomed.2025.110695_bib20","doi-asserted-by":"crossref","first-page":"19895","DOI":"10.1021\/acsomega.9b02808","article-title":"Continuous activity assay for HDAC11 enabling reevaluation of HDAC inhibitors","volume":"4","author":"Kutil","year":"2019","journal-title":"ACS Omega"},{"issue":"7","key":"10.1016\/j.compbiomed.2025.110695_bib21","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1021\/acschembio.9b00292","article-title":"Activity-guided design of HDAC11-Specific inhibitors","volume":"14","author":"Son","year":"2019","journal-title":"ACS Chem. Biol."},{"issue":"4","key":"10.1016\/j.compbiomed.2025.110695_bib22","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1021\/acschembio.2c00840","article-title":"Trapoxin A analogue as a selective nanomolar inhibitor of HDAC11","volume":"18","author":"Ho","year":"2023","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.compbiomed.2025.110695_bib23","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.ejmech.2017.04.013","article-title":"Synthesis and applications of benzohydroxamic acid-based histone deacetylase inhibitors","volume":"135","author":"De Vreese","year":"2017","journal-title":"Eur. J. Med. Chem."},{"issue":"1","key":"10.1016\/j.compbiomed.2025.110695_bib24","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1080\/14756366.2017.1417274","article-title":"Zinc binding groups for histone deacetylase inhibitors","volume":"33","author":"Zhang","year":"2018","journal-title":"J. Enzym. Inhib. Med. Chem."},{"issue":"28","key":"10.1016\/j.compbiomed.2025.110695_bib25","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.2174\/1568026619666181210152115","article-title":"Histone deacetylase inhibitors in cancer therapy","volume":"18","author":"Sun","year":"2018","journal-title":"Curr. Top. Med. Chem."},{"issue":"10","key":"10.1016\/j.compbiomed.2025.110695_bib26","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1634\/theoncologist.12-10-1247","article-title":"FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma","volume":"12","author":"Mann","year":"2007","journal-title":"Oncologist"},{"issue":"12","key":"10.1016\/j.compbiomed.2025.110695_bib27","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1158\/1078-0432.CCR-14-3119","article-title":"FDA approval: Belinostat for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma","volume":"21","author":"Lee","year":"2015","journal-title":"Clin. Cancer Res."},{"issue":"21","key":"10.1016\/j.compbiomed.2025.110695_bib28","doi-asserted-by":"crossref","first-page":"4767","DOI":"10.1158\/1078-0432.CCR-15-0530","article-title":"Panobinostat for the treatment of multiple myeloma","volume":"21","author":"Laubach","year":"2015","journal-title":"Clin. Cancer Res."},{"issue":"13","key":"10.1016\/j.compbiomed.2025.110695_bib29","doi-asserted-by":"crossref","first-page":"4694","DOI":"10.1021\/jm2003552","article-title":"Discovery of (2E)-3-{2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl}-N-hydroxyacrylamide (SB939), an orally active histone deacetylase inhibitor with a superior preclinical profile","volume":"54","author":"Wang","year":"2011","journal-title":"J. Med. Chem."},{"issue":"5","key":"10.1016\/j.compbiomed.2025.110695_bib30","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1021\/jm901453q","article-title":"Discovery of 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDc-101) as a potent multi-acting HDAC, EGFR, and HER2 inhibitor for the treatment of cancer","volume":"53","author":"Cai","year":"2010","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.compbiomed.2025.110695_bib31","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/bjh.12359","article-title":"A phase I first-in-human study with tefinostat - a monocyte\/macrophage targeted histone deacetylase inhibitor - in patients with advanced haematological malignancies","volume":"162","author":"Ossenkoppele","year":"2013","journal-title":"Br. J. Haematol."},{"issue":"2","key":"10.1016\/j.compbiomed.2025.110695_bib32","doi-asserted-by":"crossref","first-page":"2694","DOI":"10.18632\/oncotarget.13738","article-title":"Selective HDAC inhibition by ACY-241 enhances the activity of paclitaxel in solid tumor models","volume":"8","author":"Huang","year":"2017","journal-title":"Oncotarget"},{"issue":"11","key":"10.1016\/j.compbiomed.2025.110695_bib33","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/nchembio.2185","article-title":"Thermal profiling reveals phenylalanine hydroxylase as an off-target of panobinostat","volume":"12","author":"Becher","year":"2016","journal-title":"Nat. Chem. Biol."},{"issue":"8","key":"10.1016\/j.compbiomed.2025.110695_bib34","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1038\/s41589-022-01015-5","article-title":"Target deconvolution of HDAC pharmacopoeia reveals MBLAC2 as common off-target","volume":"18","author":"Lechner","year":"2022","journal-title":"Nat. Chem. Biol."},{"issue":"22","key":"10.1016\/j.compbiomed.2025.110695_bib35","doi-asserted-by":"crossref","first-page":"4143","DOI":"10.1021\/acschemneuro.4c00346","article-title":"Aromatic amino acid hydroxylases as off-targets of histone deacetylase inhibitors","volume":"15","author":"Baumann","year":"2024","journal-title":"ACS Chem. Neurosci."},{"issue":"1","key":"10.1016\/j.compbiomed.2025.110695_bib36","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/cmdc.201500486","article-title":"Why hydroxamates may not be the best histone deacetylase inhibitors\u2014what some may have forgotten or would rather forget?","volume":"11","author":"Shen","year":"2016","journal-title":"ChemMedChem"},{"key":"10.1016\/j.compbiomed.2025.110695_bib37","first-page":"1","article-title":"Designing drugs to avoid toxicity","volume":"vol. 50","author":"Smith","year":"2011"},{"issue":"1","key":"10.1016\/j.compbiomed.2025.110695_bib38","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0054522","article-title":"Glucuronidation by UGT1A1 is the dominant pathway of the metabolic disposition of belinostat in liver cancer patients","volume":"8","author":"Wang","year":"2013","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.compbiomed.2025.110695_bib39","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1097\/FPC.0b013e32833e1b37","article-title":"A pharmacogenetic study of vorinostat glucuronidation","volume":"20","author":"Kang","year":"2010","journal-title":"Pharmacogenet. Genom."},{"issue":"7","key":"10.1016\/j.compbiomed.2025.110695_bib40","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1158\/0008-5472.CAN-08-4143","article-title":"Characterization of UGTs active against SAHA and association between SAHA glucuronidation activity phenotype with UGT genotype","volume":"69","author":"Balliet","year":"2009","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.compbiomed.2025.110695_bib41","doi-asserted-by":"crossref","first-page":"369","DOI":"10.3390\/ijms23010369","article-title":"Molecular docking and biological characterization of pyrazine linked 2-Aminobenzamides as new class I selective histone deacetylase (HDAC) inhibitors with anti-leukemic activity","volume":"23","author":"Ibrahim","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"24","key":"10.1016\/j.compbiomed.2025.110695_bib42","doi-asserted-by":"crossref","first-page":"16313","DOI":"10.1021\/acs.jmedchem.2c01132","article-title":"Development of alkylated hydrazides as highly potent and selective class I histone deacetylase inhibitors with T cell modulatory properties","volume":"65","author":"Sun","year":"2022","journal-title":"J. Med. Chem."},{"issue":"11","key":"10.1016\/j.compbiomed.2025.110695_bib43","doi-asserted-by":"crossref","DOI":"10.1002\/ardp.202400437","article-title":"Development of new pyrazoles as class I HDAC inhibitors: synthesis, molecular modeling, and biological characterization in leukemia cells","volume":"357","author":"Berluti","year":"2024","journal-title":"Arch. Pharmazie"},{"issue":"3","key":"10.1016\/j.compbiomed.2025.110695_bib44","doi-asserted-by":"crossref","first-page":"3212","DOI":"10.1021\/acs.jmedchem.4c02445","article-title":"Discovery of highly potent and orally bioavailable histone deacetylase 3 inhibitors as immunomodulators and enhancers of DNA-damage response in cancer therapy","volume":"68","author":"Li","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.compbiomed.2025.110695_bib45","doi-asserted-by":"crossref","DOI":"10.1021\/acs.jmedchem.4c02373","article-title":"Exploring alternative zinc-binding groups in histone deacetylase (HDAC) inhibitors uncovers DS-103 as a potent Ethylhydrazide-Based HDAC inhibitor with chemosensitizing properties","author":"Stopper","year":"2025","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.compbiomed.2025.110695_bib46","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/S1359-6446(97)01163-X","article-title":"Virtual Screening\u2014an overview","volume":"3","author":"Walters","year":"1998","journal-title":"Drug Discov. Today"},{"issue":"23","key":"10.1016\/j.compbiomed.2025.110695_bib47","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.2174\/09298673113209990001","article-title":"Virtual screening strategies in drug discovery: a critical review","volume":"20","author":"Lavecchia","year":"2013","journal-title":"Curr. Med. Chem."},{"issue":"7958","key":"10.1016\/j.compbiomed.2025.110695_bib48","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/s41586-023-05905-z","article-title":"Computational approaches streamlining drug discovery","volume":"616","author":"Sadybekov","year":"2023","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.compbiomed.2025.110695_bib49","doi-asserted-by":"crossref","first-page":"6065","DOI":"10.1021\/acs.jcim.0c00675","article-title":"ZINC20\u2014A free ultralarge-scale chemical database for ligand discovery","volume":"60","author":"Irwin","year":"2020","journal-title":"J. Chem. Inf. Model."},{"issue":"2","key":"10.1016\/j.compbiomed.2025.110695_bib50","doi-asserted-by":"crossref","first-page":"501","DOI":"10.3390\/encyclopedia3020035","article-title":"Molecular filters in medicinal chemistry","volume":"3","author":"Kralj","year":"2023","journal-title":"Encyclopedia"},{"issue":"1","key":"10.1016\/j.compbiomed.2025.110695_bib51","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S1056-8719(00)00107-6","article-title":"Drug-like properties and the causes of poor solubility and poor permeability","volume":"44","author":"Lipinski","year":"2000","journal-title":"J. Pharmacol. Toxicol. Methods"},{"issue":"3","key":"10.1016\/j.compbiomed.2025.110695_bib52","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0169-409X(02)00003-0","article-title":"Prediction of 'drug-likeness'","volume":"54","author":"Walters","year":"2002","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"4","key":"10.1016\/j.compbiomed.2025.110695_bib53","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/nrd1063","article-title":"Designing screens: how to make your hits a hit","volume":"2","author":"Walters","year":"2003","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1\u20133","key":"10.1016\/j.compbiomed.2025.110695_bib54","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(00)00129-0","article-title":"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings","volume":"46","author":"Lipinski","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.compbiomed.2025.110695_bib55","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.ijbiomac.2022.12.252","article-title":"Identification of probable inhibitors for the DNA polymerase of the monkeypox virus through the virtual screening approach","volume":"229","author":"Kumari","year":"2023","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.compbiomed.2025.110695_bib56","series-title":"Chemoinformatics and Computational Chemical Biology","first-page":"175","article-title":"Bayesian methods in virtual screening and chemical biology","author":"Bender","year":"2011"},{"issue":"3","key":"10.1016\/j.compbiomed.2025.110695_bib57","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.drudis.2014.10.012","article-title":"Machine-learning approaches in drug discovery: methods and applications","volume":"20","author":"Lavecchia","year":"2015","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.compbiomed.2025.110695_bib58","doi-asserted-by":"crossref","first-page":"311","DOI":"10.3390\/ddc2020017","article-title":"Virtual screening algorithms in drug discovery: a review focused on machine and deep learning methods","volume":"2","author":"Oliveira","year":"2023","journal-title":"Drugs Drug Candidates"},{"issue":"1","key":"10.1016\/j.compbiomed.2025.110695_bib59","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1021\/ci7003253","article-title":"Na\u00efve bayes classification using 2D pharmacophore feature triplet vectors","volume":"48","author":"Watson","year":"2008","journal-title":"J. Chem. Inf. Model."},{"issue":"1","key":"10.1016\/j.compbiomed.2025.110695_bib60","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s13321-016-0148-0","article-title":"Comparing structural fingerprints using a literature-based similarity benchmark","volume":"8","author":"O'Boyle","year":"2016","journal-title":"J. Cheminf."},{"issue":"5","key":"10.1016\/j.compbiomed.2025.110695_bib61","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1021\/ci100062n","article-title":"Large-scale systematic analysis of 2D fingerprint methods and parameters to improve virtual screening enrichments","volume":"50","author":"Sastry","year":"2010","journal-title":"J. Chem. Inf. Model."},{"issue":"7","key":"10.1016\/j.compbiomed.2025.110695_bib62","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1177\/1087057105281365","article-title":"Using extended-connectivity fingerprints with Laplacian-modified Bayesian analysis in high-throughput screening follow-up","volume":"10","author":"Rogers","year":"2005","journal-title":"J. Biomol. Screen"},{"issue":"5","key":"10.1016\/j.compbiomed.2025.110695_bib63","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1021\/ci100050t","article-title":"Extended-connectivity fingerprints","volume":"50","author":"Rogers","year":"2010","journal-title":"J. Chem. Inf. Model."},{"issue":"5","key":"10.1016\/j.compbiomed.2025.110695_bib64","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1007\/s00204-022-03252-y","article-title":"Prediction reliability of QSAR models: an overview of various validation tools","volume":"96","author":"De","year":"2022","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.compbiomed.2025.110695_bib65","series-title":"Computational Toxicology: Volume II","first-page":"3","article-title":"Methods for building QSARs","author":"Devillers","year":"2013"},{"key":"10.1016\/j.compbiomed.2025.110695_bib66","series-title":"Chemoinformatics: Basic Concepts and Methods","first-page":"465","article-title":"QSAR\/QSPR revisited","author":"Golbraikh","year":"2018"},{"issue":"8","key":"10.1016\/j.compbiomed.2025.110695_bib67","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1007\/s11095-008-9609-0","article-title":"QSAR modeling of the blood-brain barrier permeability for diverse organic compounds","volume":"25","author":"Zhang","year":"2008","journal-title":"Pharm. Res."},{"key":"10.1016\/j.compbiomed.2025.110695_bib68","series-title":"Applied Chemoinformatics: Achievements and Future Opportunities","first-page":"9","article-title":"QSAR\/QSPR","author":"Sippl","year":"2018"},{"issue":"12","key":"10.1016\/j.compbiomed.2025.110695_bib69","doi-asserted-by":"crossref","first-page":"8486","DOI":"10.1021\/acs.jmedchem.1c00420","article-title":"Development of HDAC inhibitors exhibiting therapeutic potential in T-Cell prolymphocytic leukemia","volume":"64","author":"Toutah","year":"2021","journal-title":"J. Med. Chem."},{"issue":"5","key":"10.1016\/j.compbiomed.2025.110695_bib70","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1021\/acs.jmedchem.0c01922","article-title":"Unique molecular interaction with the histone deacetylase 6 catalytic tunnel: crystallographic and biological characterization of a model chemotype","volume":"64","author":"Olaoye","year":"2021","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.compbiomed.2025.110695_bib71","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1021\/acs.jmedchem.1c01585","article-title":"Discovery of HDAC6-Selective inhibitor NN-390 with in vitro efficacy in group 3 medulloblastoma","volume":"65","author":"Nawar","year":"2022","journal-title":"J. Med. Chem."},{"issue":"8","key":"10.1016\/j.compbiomed.2025.110695_bib72","doi-asserted-by":"crossref","first-page":"4810","DOI":"10.1021\/acs.jmedchem.0c02210","article-title":"Tetrahydroquinoline-capped histone deacetylase 6 inhibitor SW-101 ameliorates pathological phenotypes in a charcot\u2013marie\u2013tooth type 2A mouse model","volume":"64","author":"Shen","year":"2021","journal-title":"J. Med. Chem."},{"issue":"11","key":"10.1016\/j.compbiomed.2025.110695_bib73","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.3390\/ph15111321","article-title":"High efficacy and drug synergy of HDAC6-Selective inhibitor NN-429 in natural killer (NK)\/T-Cell lymphoma","volume":"15","author":"Garcha","year":"2022","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.compbiomed.2025.110695_bib74","series-title":"Hdac Inhibitors and Therapeutic Methods Using the Same WO2012106343A2","author":"Kozikowski","year":"2012"},{"issue":"16","key":"10.1016\/j.compbiomed.2025.110695_bib75","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1016\/j.bmcl.2019.06.006","article-title":"Synthesis of N'-propylhydrazide analogs of hydroxamic inhibitors of histone deacetylases (HDACs) and evaluation of their impact on activities of HDACs and replication of hepatitis C virus (HCV)","volume":"29","author":"Kozlov","year":"2019","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.compbiomed.2025.110695_bib76","doi-asserted-by":"crossref","DOI":"10.1016\/j.compbiomed.2023.107700","article-title":"Utilization of AlphaFold models for drug discovery: feasibility and challenges. Histone deacetylase 11 as a case study","author":"Baselious","year":"2023","journal-title":"Comput. Biol. Med."},{"issue":"10","key":"10.1016\/j.compbiomed.2025.110695_bib77","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1021\/acschembio.6b00396","article-title":"HDAC8 catalyzes the hydrolysis of long chain fatty acyl lysine","volume":"11","author":"Aramsangtienchai","year":"2016","journal-title":"ACS Chem. Biol."},{"issue":"5","key":"10.1016\/j.compbiomed.2025.110695_bib78","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1021\/acs.biochem.5b01327","article-title":"General base-general acid catalysis in human histone deacetylase 8","volume":"55","author":"Gantt","year":"2016","journal-title":"Biochemistry"},{"issue":"9","key":"10.1016\/j.compbiomed.2025.110695_bib79","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/nchembio.2134","article-title":"Histone deacetylase 6 structure and molecular basis of catalysis and inhibition","volume":"12","author":"Hai","year":"2016","journal-title":"Nat. Chem. Biol."},{"issue":"22","key":"10.1016\/j.compbiomed.2025.110695_bib80","doi-asserted-by":"crossref","first-page":"10000","DOI":"10.1021\/acs.jmedchem.8b01087","article-title":"Characterization of histone deacetylase 8 (HDAC8) selective inhibition reveals specific active site structural and functional determinants","volume":"61","author":"Marek","year":"2018","journal-title":"J. Med. Chem."},{"issue":"5","key":"10.1016\/j.compbiomed.2025.110695_bib81","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1002\/wcms.31","article-title":"Metadynamics","volume":"1","author":"Barducci","year":"2011","journal-title":"WIREs Comput. Mol. Sci."},{"issue":"3","key":"10.1016\/j.compbiomed.2025.110695_bib82","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1021\/acs.jcim.9b00843","article-title":"Exploring ligand stability in protein crystal structures using binding pose metadynamics","volume":"60","author":"Fusani","year":"2020","journal-title":"J. Chem. Inf. Model."},{"issue":"6","key":"10.1016\/j.compbiomed.2025.110695_bib83","doi-asserted-by":"crossref","first-page":"2990","DOI":"10.1021\/acs.jctc.6b00201","article-title":"Prediction of protein-ligand binding poses via a combination of induced fit docking and metadynamics simulations","volume":"12","author":"Clark","year":"2016","journal-title":"J. Chem. Theor. Comput."},{"key":"10.1016\/j.compbiomed.2025.110695_bib84","series-title":"Schr\u00f6dinger Release 2019-1","year":"2019"},{"issue":"3","key":"10.1016\/j.compbiomed.2025.110695_bib85","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s10822-013-9644-8","article-title":"Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments","volume":"27","author":"Sastry","year":"2013","journal-title":"J. Comput. Aided Mol. Des."},{"key":"10.1016\/j.compbiomed.2025.110695_bib86","series-title":"Schr\u00f6dinger Release 2019-1: Protein Preparation Wizard","year":"2019"},{"key":"10.1016\/j.compbiomed.2025.110695_bib87","series-title":"Schr\u00f6dinger Release 2019-1","year":"2019"},{"issue":"6\u20137","key":"10.1016\/j.compbiomed.2025.110695_bib88","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s10822-010-9349-1","article-title":"Towards the comprehensive, rapid, and accurate prediction of the favorable tautomeric states of drug-like molecules in aqueous solution","volume":"24","author":"Greenwood","year":"2010","journal-title":"J. Comput. Aided Mol. Des."},{"issue":"12","key":"10.1016\/j.compbiomed.2025.110695_bib89","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/s10822-007-9133-z","article-title":"Epik: a software program for pK(a) prediction and protonation state generation for drug-like molecules","volume":"21","author":"Shelley","year":"2007","journal-title":"J. Comput. Aided Mol. Des."},{"key":"10.1016\/j.compbiomed.2025.110695_bib90","series-title":"Schr\u00f6dinger Release 2019-1","year":"2019"},{"key":"10.1016\/j.compbiomed.2025.110695_bib91","series-title":"Schr\u00f6dinger Release 2019-1: Glide","year":"2019"},{"issue":"7","key":"10.1016\/j.compbiomed.2025.110695_bib92","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1021\/jm0306430","article-title":"Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy","volume":"47","author":"Friesner","year":"2004","journal-title":"J. Med. Chem."},{"issue":"21","key":"10.1016\/j.compbiomed.2025.110695_bib93","doi-asserted-by":"crossref","first-page":"6177","DOI":"10.1021\/jm051256o","article-title":"Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes","volume":"49","author":"Friesner","year":"2006","journal-title":"J. Med. Chem."},{"issue":"7","key":"10.1016\/j.compbiomed.2025.110695_bib94","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1021\/jm030644s","article-title":"A new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening","volume":"47","author":"Halgren","year":"2004","journal-title":"J. Med. Chem."},{"issue":"45","key":"10.1016\/j.compbiomed.2025.110695_bib95","doi-asserted-by":"crossref","first-page":"11225","DOI":"10.1021\/ja9621760","article-title":"Development and testing of the OPLS all-atom force field on conformational energetics and properties of organic liquids","volume":"118","author":"Jorgensen","year":"1996","journal-title":"J. Am. Chem. Soc."},{"issue":"6","key":"10.1016\/j.compbiomed.2025.110695_bib96","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1021\/ja00214a001","article-title":"The OPLS [optimized potentials for liquid simulations] potential functions for proteins, energy minimizations for crystals of cyclic peptides and crambin","volume":"110","author":"Jorgensen","year":"1988","journal-title":"J. Am. Chem. Soc."},{"issue":"1","key":"10.1016\/j.compbiomed.2025.110695_bib97","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1021\/acs.jctc.5b00864","article-title":"OPLS3: a force field providing broad coverage of drug-like small molecules and proteins","volume":"12","author":"Harder","year":"2016","journal-title":"J. Chem. Theor. Comput."},{"issue":"5","key":"10.1016\/j.compbiomed.2025.110695_bib98","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1021\/ct900587b","article-title":"Prediction of absolute solvation free energies using molecular dynamics free energy perturbation and the OPLS force field","volume":"6","author":"Shivakumar","year":"2010","journal-title":"J. Chem. Theor. Comput."},{"key":"10.1016\/j.compbiomed.2025.110695_bib99","series-title":"Desmond Molecular Dynamics System","year":"2019"},{"key":"10.1016\/j.compbiomed.2025.110695_bib100","series-title":"SC '06: Proceedings of the 2006 ACM\/IEEE Conference on Supercomputing","article-title":"Scalable algorithms for molecular dynamics simulations on commodity clusters","author":"Bowers","year":"2006"},{"key":"10.1016\/j.compbiomed.2025.110695_bib101","series-title":"Schr\u00f6dinger Release 2019-1: Qikprop","year":"2019"},{"key":"10.1016\/j.compbiomed.2025.110695_bib102","series-title":"Schr\u00f6dinger Release 2019-1: Canvas","year":"2019"},{"issue":"2","key":"10.1016\/j.compbiomed.2025.110695_bib103","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.jmgm.2010.05.008","article-title":"Analysis and comparison of 2D fingerprints: insights into database screening performance using eight fingerprint methods","volume":"29","author":"Duan","year":"2010","journal-title":"J. Mol. Graph. Model."},{"issue":"5","key":"10.1016\/j.compbiomed.2025.110695_bib104","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1021\/ci060132x","article-title":"A novel automated lazy learning QSAR (ALL-QSAR) approach: method development, applications, and virtual screening of chemical databases using validated ALL-QSAR models","volume":"46","author":"Zhang","year":"2006","journal-title":"J. Chem. Inf. Model."},{"issue":"1","key":"10.1016\/j.compbiomed.2025.110695_bib105","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/qsar.200390007","article-title":"The importance of being earnest: validation is the absolute essential for successful application and interpretation of QSPR models","volume":"22","author":"Tropsha","year":"2003","journal-title":"QSAR Comb. Sci."},{"issue":"4","key":"10.1016\/j.compbiomed.2025.110695_bib106","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1021\/acs.jcim.2c01253","article-title":"ZINC-22\u2500A free multi-billion-scale database of tangible compounds for ligand discovery","volume":"63","author":"Tingle","year":"2023","journal-title":"J. Chem. Inf. Model."},{"issue":"48","key":"10.1016\/j.compbiomed.2025.110695_bib107","doi-asserted-by":"crossref","first-page":"4777","DOI":"10.1021\/acs.biochem.9b00786","article-title":"One-atom substitution enables direct and continuous monitoring of histone deacylase activity","volume":"58","author":"Zessin","year":"2019","journal-title":"Biochemistry"},{"issue":"24","key":"10.1016\/j.compbiomed.2025.110695_bib108","doi-asserted-by":"crossref","first-page":"10188","DOI":"10.1021\/acs.jmedchem.7b01447","article-title":"Structure-based design and biological characterization of selective histone deacetylase 8 (HDAC8) inhibitors with anti-neuroblastoma activity","volume":"60","author":"Heimburg","year":"2017","journal-title":"J. Med. Chem."}],"container-title":["Computers in Biology and Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010482525010467?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010482525010467?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,26]],"date-time":"2026-04-26T08:40:38Z","timestamp":1777192838000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0010482525010467"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":108,"alternative-id":["S0010482525010467"],"URL":"https:\/\/doi.org\/10.1016\/j.compbiomed.2025.110695","relation":{"has-preprint":[{"id-type":"doi","id":"10.26434\/chemrxiv-2025-1zw6n","asserted-by":"object"}]},"ISSN":["0010-4825"],"issn-type":[{"value":"0010-4825","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In silico screening of a designed focused chemical space identifies novel alkyl hydrazides as potent HDAC11 inhibitors","name":"articletitle","label":"Article Title"},{"value":"Computers in Biology and Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.compbiomed.2025.110695","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"110695"}}